Patents by Inventor Roberta Cannella

Roberta Cannella has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250235473
    Abstract: Injectable dosages and formulations of fosnetupitant and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy.
    Type: Application
    Filed: December 23, 2024
    Publication date: July 24, 2025
    Inventors: Alessio Venturini, Roberta Cannella
  • Patent number: 12208109
    Abstract: Injectable dosages and formulations of fosnetupitant and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy.
    Type: Grant
    Filed: November 15, 2022
    Date of Patent: January 28, 2025
    Assignee: Helsinn Healthcare SA
    Inventors: Alessio Venturini, Roberta Cannella
  • Patent number: 12071421
    Abstract: Disclosed are compounds including phosphate and N-oxide prodrugs of the NK1 antagonist netupitant, useful in the prevention and/or treatment of diseases including emesis induced by chemotherapy. Also disclosed are methods of making a di-tert-butyl (chloromethyl) phosphate useful in the manufacture of such prodrugs by reacting a dialkylphosphate salt with an acid to obtain the corresponding ester of phosphoric acid, reacting the ester with a quaternary ammonium hydroxide base to form a monobasic salt, and reacting the monobasic salt with chloroiodomethane to form the corresponding chloromethyl dialkyl phosphate.
    Type: Grant
    Filed: March 21, 2022
    Date of Patent: August 27, 2024
    Assignee: Helsinn Healthcare SA
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stella
  • Patent number: 12042494
    Abstract: Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.
    Type: Grant
    Filed: December 16, 2022
    Date of Patent: July 23, 2024
    Assignee: Helsinn Healthcare SA
    Inventors: Fabio Trento, Sergio Cantoreggi, Giorgia Rossi, Roberta Cannella, Daniele Bonadeo
  • Publication number: 20230263799
    Abstract: Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.
    Type: Application
    Filed: December 16, 2022
    Publication date: August 24, 2023
    Inventors: Fabio TRENTO, Sergio Cantoreggi, Giorgia Rossi, Roberta Cannella, Daniele Bonadeo
  • Publication number: 20230172953
    Abstract: Injectable dosages and formulations of fosnetupitant and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy.
    Type: Application
    Filed: November 15, 2022
    Publication date: June 8, 2023
    Inventors: Alessio Venturini, Roberta Cannella
  • Patent number: 11559523
    Abstract: Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.
    Type: Grant
    Filed: October 21, 2020
    Date of Patent: January 24, 2023
    Assignee: Helsinn Healthcare SA
    Inventors: Fabio Trento, Sergio Cantoreggi, Giorgia Rossi, Roberta Cannella, Daniele Bonadeo
  • Publication number: 20220401463
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.
    Type: Application
    Filed: March 21, 2022
    Publication date: December 22, 2022
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stella
  • Patent number: 11529362
    Abstract: Injectable dosages and formulations of fosnetupitant and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: December 20, 2022
    Assignee: Helsinn Healthcare SA
    Inventors: Alessio Venturini, Roberta Cannella
  • Patent number: 11312698
    Abstract: Fosnetupitant chloride hydrochloride having improved stability, characterized by the following chemical structure:
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: April 26, 2022
    Assignee: Helsinn Healthcare SA
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stella
  • Publication number: 20210100794
    Abstract: Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.
    Type: Application
    Filed: October 21, 2020
    Publication date: April 8, 2021
    Inventors: Fabio TRENTO, Sergio CANTOREGGI, Giorgia ROSSI, Roberta CANNELLA, Daniele BONADEO
  • Publication number: 20200399240
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.
    Type: Application
    Filed: June 8, 2020
    Publication date: December 24, 2020
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stella
  • Patent number: 10828297
    Abstract: Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: November 10, 2020
    Assignee: Helsinn Healthcare SA
    Inventors: Fabio Trento, Sergio Cantoreggi, Giorgia Rossi, Roberta Cannella, Daniele Bonadeo
  • Patent number: 10717721
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: July 21, 2020
    Assignee: Helsinn Healthcare SA
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stella
  • Publication number: 20200206249
    Abstract: Injectable dosages and formulations of fosnetupitant and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 2, 2020
    Inventors: Alessio Venturini, Roberta Cannella
  • Patent number: 10624911
    Abstract: Injectable dosages and formulations of fosnetupitant and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: April 21, 2020
    Assignee: Helsinn Healthcare SA
    Inventors: Alessio Venturini, Roberta Cannella
  • Publication number: 20190177296
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.
    Type: Application
    Filed: December 21, 2018
    Publication date: June 13, 2019
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stella
  • Patent number: 10208073
    Abstract: Disclosed is a solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium (fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone and its application in methods for preventing acute and delayed nausea and vomiting in a human patient receiving highly emetogenic cancer chemotherapy.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: February 19, 2019
    Assignee: Helsinn Healthcare SA
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J Stella
  • Publication number: 20180256567
    Abstract: Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.
    Type: Application
    Filed: March 16, 2018
    Publication date: September 13, 2018
    Inventors: Fabio TRENTO, Sergio CANTOREGGI, Giorgia ROSSI, Roberta CANNELLA, Daniele BONADEO
  • Publication number: 20180194788
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.
    Type: Application
    Filed: January 18, 2018
    Publication date: July 12, 2018
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stella